Clinical Trials Logo

Hemodialysis clinical trials

View clinical trials related to Hemodialysis.

Filter by:

NCT ID: NCT03499054 Completed - Fatigue Clinical Trials

Breathing Exercises to Improve Fatigue and Quality of Life in Hemodialysis Patients

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

Breathing exercises to improve fatigue and quality of life in hemodialysis patients

NCT ID: NCT03480568 Not yet recruiting - Clinical trials for Hypercholesterolemia

Alirocumab in Patients on a Stable Dialysis Regimen

Start date: May 1, 2018
Phase: Phase 3
Study type: Interventional

12-week study of the efficacy and safety of alirocumab in patients maintained stably on hemodialysis or peritoneal dialysis. Measures of cholesterol levels, drug levels, PCSK9 levels, routine chemistry and cell counts, and biomarkers will be obtained at baseline and at weeks 4, 8, 10 and 12 weeks. Safety events will be obtained throughout the study.

NCT ID: NCT03471299 Completed - Hemodialysis Clinical Trials

Association of Survival in Impact of Ultrafiltration Rates in Hemodialysis Patients

Start date: April 1, 2017
Phase:
Study type: Observational

This study assesses retrospectively the association of mortality on UFR assessments in our study population undergoing HD.

NCT ID: NCT03470727 Completed - Hemodialysis Clinical Trials

The Effect of Citrate Dialysate on Clot Formation and Anemia in Hemodialysis Patients

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

Acetate-free citrate containing dialysate is expected to be clinically effective in maintaining hemodynamic stability during hemodialysis (HD). It has been demonstrated that citrate dialysate help produce a local anticoagulant effect by chelating ionized calcium. Moreover, citrate can improve phosphate and beta2 macroglobulin and better control of arterial hypertension and hemoglobinemia. We therefore would like to study the effect of citrate dialysate on clot formation and anemia while reducing heparin in chronic hemodialysis patients.

NCT ID: NCT03440853 Recruiting - Clinical trials for End-Stage Renal Disease

Technology Assisted Stepped Collaborative Care Intervention

TASCCI
Start date: March 28, 2018
Phase: N/A
Study type: Interventional

This study evaluates a collaborative care intervention in reducing depression, fatigue and pain symptoms and improving health related quality of life in hemodialysis patients. Half of participants will receive the collaborative care intervention, while the other half will receive technology delivered health education information.

NCT ID: NCT03419923 Recruiting - Hemodialysis Clinical Trials

Three Anticoagulation Strategies for Hemodialysis in Patients at Risk of Hemorrhage

TASHA
Start date: October 1, 2017
Phase: N/A
Study type: Interventional

The aim of our study is to assess three anticoagulation strategies for intermittent hemodialysis(IHD) in patients at risk of hemorrhage. A registry of consecutive hemodialysis patients with high risk of hemorrhage were conducted at the Guangdong General Hospital, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, the Second Affiliated Hospital of Guangzhou Medicine University or Guangzhou Hospital of Chinese Medicine, between October 1st, 2017 and June 30th,2018. In this multi-center prospective and randomized study, participants were randomly divided into three groups during IHD according to different anticoagulation, including with regular saline flushes, one stage regional citrate anticoagulation (RCA) and two-stage RCA.

NCT ID: NCT03365635 Not yet recruiting - Hepatitis C Clinical Trials

Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C

HD
Start date: June 15, 2018
Phase: Phase 4
Study type: Interventional

This is a study to define strategies for Nephrologists to directly supervise and apply direct acting antivirals to cure hepatitis C in hemodialysis patients. Strategies will include identification of candidate patients, application for insurance approval, specifics of direct acting antiviral therapy (Zepatier with or without ribavirin) and laboratory monitoring during and after therapy.

NCT ID: NCT03353844 Recruiting - Clinical trials for End Stage Renal Disease

The Effects of Intradialytic Exercise in Hemodiafiltration Patients

Start date: November 9, 2017
Phase: N/A
Study type: Interventional

Low physical activity is associated with in hemodialysis and hemodiafiltration (HDF) patients. Previous studies showed the benefits of intradialytic exercise for improvement of physical fitness and hemodialysis adequacy. However, the effect of intradialytic exercise on physical activity has not been explored. This current open-labelled randomized controlled trial is conducted in HDF patients to determine the effect of intradialytic exercise program for 6 months on daily physical activity measured by tri-axial accelerometer (wearable device).

NCT ID: NCT03350308 Recruiting - Hypotension Clinical Trials

Prediction of Risk of Hypotension in Hemodialysis

IMHOTEP
Start date: January 1, 2015
Phase: N/A
Study type: Observational

The main objective is to establish a statistical predictive model of the risk of intradialytic hypotension during hemodialysis (HD) or hemodiafiltration (HDF) sessions based on the measurement of residual blood volume and excess extracellular hydration. The secondary objective is to study the impact of dysfunction in the mechanisms of compensation for decreased blood volume (heart disease, neuropathy, drugs) on the risk of intradialytic hypotension.

NCT ID: NCT03311321 Recruiting - Clinical trials for Cardiovascular Diseases

Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients

Start date: September 13, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The life span of adults with end-stage renal disease is reduced, and cardiovascular disease (CVD) accounts for approximately half the deaths among those undergoing hemodialysis (HD). Vascular calcification is a key process in the development of atherosclerotic and arteriosclerotic CVD, and contributes significantly to the greater mortality rates and CVD events in HD patients. Recently, there has been growing interest in the vitamin K-dependent matrix Gla protein (MGP) and its role in inhibiting vascular calcification. Animal studies have revealed that the vitamin K-dependent protein MGP may reduce the progression of vascular calcification, possibly by means of improving vascular function. The relationship between MGP and vitamin K lies in the fact that inactive matrix Gla protein requires vitamin K to carboxylate it for its activation. Currently, data in HD patients are scant and equivocal on the effects of vitamin K supplementation on CVD risk outcomes. Therefore, the purpose of this 8-week randomized, placebo-controlled, double-blind clinical trial is to determine whether daily vitamin K supplementation can favorably alter measurements of endothelial function and arterial stiffness in HD patients.